Shinpoong Pharmaceutical Co Ltd Total Assets
Shinpoong Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Shinpoong Pharmaceutical Co Ltd (019175) holds total assets worth ₩366.50 Billion KRW (≈ $248.37 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Shinpoong Pharmaceutical Co Ltd worth for the company's overall valuation and market capitalisation.
Total Assets of Shinpoong Pharmaceutical Co Ltd (2014–2025)
Total assets of Shinpoong Pharmaceutical Co Ltd from 2014 to 2025. This chart illustrates how Shinpoong Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See latest Shinpoong Pharmaceutical Co Ltd stock price today for real-time trading data and today's change.
Shinpoong Pharmaceutical Co Ltd - Asset Composition Analysis
Shinpoong Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
Shinpoong Pharmaceutical Co Ltd total assets breakdown as of December 2025. Shinpoong Pharmaceutical Co Ltd's total assets of ₩366.50 Billion consist of 58.7% current assets and 41.4% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 13.5% |
| Accounts Receivable | ₩72.54 Billion | 20.6% |
| Inventory | ₩58.48 Billion | 16.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩5.09 Billion | 1.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Shinpoong Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Shinpoong Pharmaceutical Co Ltd short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shinpoong Pharmaceutical Co Ltd's current assets represent 58.7% of total assets in 2025, an increase from 51.6% in 2014.
- Cash Position: Cash and equivalents constituted 13.5% of total assets in 2025, up from 1.5% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 3.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 20.6% of total assets.
Shinpoong Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Shinpoong Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Shinpoong Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.86 | 2.59 | 8.64 |
| Quick Ratio | 2.02 | 1.77 | 7.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩137.88 Billion | ₩115.96 Billion | ₩237.99 Billion |
Shinpoong Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shinpoong Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.83 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 3.0% |
| Total Assets | ₩352.47 Billion |
| Market Capitalization | $16.98 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shinpoong Pharmaceutical Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shinpoong Pharmaceutical Co Ltd's assets grew by 3.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shinpoong Pharmaceutical Co Ltd (2014–2025)
The table below shows the annual total assets of Shinpoong Pharmaceutical Co Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩352.47 Billion ≈ $238.86 Million |
+3.03% |
| 2024-12-31 | ₩342.09 Billion ≈ $231.83 Million |
-2.28% |
| 2023-12-31 | ₩350.08 Billion ≈ $237.25 Million |
-3.17% |
| 2022-12-31 | ₩361.54 Billion ≈ $245.01 Million |
-7.91% |
| 2021-12-31 | ₩392.58 Billion ≈ $266.05 Million |
-19.41% |
| 2020-12-31 | ₩487.15 Billion ≈ $330.13 Million |
+28.16% |
| 2019-12-31 | ₩380.11 Billion ≈ $257.60 Million |
-0.22% |
| 2018-12-31 | ₩380.95 Billion ≈ $258.17 Million |
-1.21% |
| 2017-12-31 | ₩385.61 Billion ≈ $261.32 Million |
-7.41% |
| 2016-12-31 | ₩416.49 Billion ≈ $282.25 Million |
+1.40% |
| 2015-12-31 | ₩410.73 Billion ≈ $278.35 Million |
+0.35% |
| 2014-12-31 | ₩409.30 Billion ≈ $277.37 Million |
-- |
About Shinpoong Pharmaceutical Co Ltd
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial dru… Read more